Baicheng Pharmaceutical announced that it has signed a "Technology Development (Cooperation) Agreement" with Peking Yuanfang Tongda Pharmaceutical Technology Co., Ltd., transferring 70% of the ownership of Type 2 modified new drug 2022HY052 for 70 million yuan. The company will continue to be responsible for the research and development, clinical trials, and production of the drug. The agreement will take effect from the date of mutual signature and seal, and is expected to have a positive impact on the company's operating performance in 2024 and future years.
百诚医药：2类改良型新药2022HY052技术转让 金额为7000万元
Baicheng Medicine: Technology transfer of class 2 modified new drug 2022HY052, with an amount of 70 million yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.